Compare DAIO & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | RNAZ |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 27.9M |
| IPO Year | 2026 | 2021 |
| Metric | DAIO | RNAZ |
|---|---|---|
| Price | $2.62 | $1.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 28.4K | 19.2K |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,500,000.00 | N/A |
| Revenue This Year | $3.26 | N/A |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.16 | $1.28 |
| 52 Week High | $4.49 | $12.60 |
| Indicator | DAIO | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 25.80 |
| Support Level | $2.28 | N/A |
| Resistance Level | $2.73 | $1.93 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 58.33 | 6.42 |
Data I/O Corp provides semiconductor programming, security provisioning, and intellectual property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices and secure microcontrollers. It operates as a single segment entity, with the sole objective to design, manufacture, and sell programming solutions and Programming-as-a-Service (PaaS) to the world's various electronics manufacturers including OEMs, CMs and EMS companies. The company operate in three separate locations Redmond, Washington; Shanghai, China; and Munich, Germany.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.